Phase 2 N=151 A Study in Subjects With Recurrent Malignant Glioma
Glioma
Primary: Progression Free Survival (PFS) Rate at Month 6 — 11.0; 21.2; 8.0; 7.6 Percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=47 Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma
Brain and Central Nervous System Tumors
Primary: Progression-free Survival (PFS) Rate at 6 Months — 19 percentage of participants
Phase 2 N=31 Low Dose Radiation Therapy for Glioblastoma Multiforme
High Grade Glioma
Primary: Response Rate
Phase 1 N=3 Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma
Glioma · Anaplastic Astrocytoma · Anaplastic Oligodendroglioma
Primary: Percentage of Dose-limiting Toxicities — 0; 0; 17 Percentage of dose-limiting toxicities
Phase 2 N=60 Temozolomide in Treating Patients With Recurrent High-Grade Glioma
Recurrent Central Nervous System Neoplasm
Primary: 6 Month Progression-free Survival — 10; 50 percentage of patients
Phase 2 N=72 Gliadel Wafer and Fluorescence-Guided Surgery With 5-ALA Followed by Radiation Therapy And Temozolomide in Treating Patients With Primary Glioblastoma
Glioblastoma
Primary: Safety, Tolerability, and Feasibility of Combination Intra-operative 5-ALA and Gliadel Wafers Prior to Adjuvant Radiotherapy Plus Temozolomide — 62; 9; 6; 45 Participants
Phase 2 N=120 Temozolomide in Treating Patients With Low-Grade Glioma
CNS Tumor, Adult
Primary: Response Rate (Complete and Partial Response) — 7 Participants
Phase 2 N=30 Spectroscopic MRI-Guided Radiation Therapy Planning in Glioblastoma
Glioblastoma · Gliosarcoma
Primary: Feasibility as Assessed by Successful Co-registration of sMRI-based Treatment Volumes With Clinical Images Into the Radiation Treatment Execution Platform — 30…
Phase 2 N=31 Sunitinib in Treating Patients With Recurrent Malignant Gliomas
Adult Anaplastic Astrocytoma · Adult Diffuse Astrocytoma · Adult Giant Cell Glioblastoma
Primary: Progression-free Survival at 6 Months (Stratum 1) — 1 patients
Phase 2 N=136 Temozolomide and Radiation Therapy in Treating Patients With Gliomas
Brain and Central Nervous System Tumors
Primary: Overall Survival Rate at 3 Years — 73.1 percentage of participants — p=<0.001
Phase 2 N=121 Lerapolturev in Recurrent Malignant Glioma
Malignant Glioma
Primary: Number of Participants With Objective Radiographic Response — 5; 2 Participants
N/A N=11 Measuring Fatty Acid Oxidation in Gliomas Using 18F-FPIA PET/MRI
Glioma
Primary: Quantitative Measurement of [18F]-FPIA Uptake in Human Gliomas — 0.9041; 1.3529; 2.0470 SUV60_max
N/A N=11 Image-Guided Stereotactic Biopsy of High Grade Gliomas
Brain Cancer · Glioma
Primary: Invest Relation Btw Voxel-based Determ of Prolif Rate & Obser MR Imaging Featu (i.e., Ktrans or Microvas Permeabil; fBV, Tiss Fract Blood Vol), as Well With Spatially…
Phase 2 N=92 Radiation Therapy in Treating Young Patients With Gliomas
Brain Tumor · Central Nervous System Tumor
Primary: Marginal-failure Rate — 0 percentage of failure rate
Phase 2 N=88 Bevacizumab for Recurrent Malignant Glioma
Recurrent High-Grade Gliomas · Malignant Gliomas
Primary: Percentage of Participants With Progression Free Survival at 6 Months. — 20.9; 29 Percentage of participants
Phase 3 N=1,125 Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
Brain and Central Nervous System Tumors
Primary: Median Overall Survival Time — 16.6; 14.9 months — p=0.63
Phase 2 N=36 AMG 102 and Avastin for Recurrent Malignant Glioma
Glioblastoma Multiforme · Gliosarcoma
Primary: Radiographic Response — 27.8 percentage of participants
Phase 3 N=716 An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)
Brain Neoplasms
Primary: Progression-free Survival (PFS) Determined by BICR — 10.64; 10.32 Months
Phase 2 N=5 Vaccine for Patients With Newly Diagnosed or Recurrent Low-Grade Glioma
Adult Diffuse Astrocytoma · Adult Mixed Glioma · Adult Oligodendroglioma
Primary: Progression-free Survival (PFS) of Low Grade Glioma Patients Treated With Autologous Dendritic Cells Pulsed With Autologous Tumor Lysate — 0; 1; 1; 1 participants
Phase 3 N=108 Gleolan for Visualization of Newly Diagnosed or Recurrent Meningioma
Meningioma
Primary: The Percentage of Participants Who Had at Least 1 Indeterminate Tissue or Unexpected Fluorescent End of Surgery (EOS) Tissue Where Gleolan-induced PpIX Fluorescence…
Phase 2 N=118 Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas
Anaplastic Astrocytoma · Central Nervous System Neoplasm · Glioblastoma
Primary: One Year Overall Survival — 0.7208 Estimated probability
Phase 2 N=112 Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Adult Giant Cell Glioblastoma · Adult Glioblastoma · Adult Gliosarcoma
Primary: Dose Limiting Toxicities of EMD + RT and TMZ — 0; 0; 0 participants
Phase 2 N=58 VEGF Trap in Treating Patients With Recurrent Malignant Gliomas That Did Not Respond to Temozolomide
Adult Anaplastic Astrocytoma · Adult Anaplastic Oligodendroglioma · Adult Giant Cell Glioblastoma
Primary: Progression-free Survival (PFS) at 6 Months — 25; 7.7 percentage of participants
Phase 1 N=9 Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Anaplastic Astrocytoma
Glioblastoma Multiforme/Anaplastic Astrocytoma
Primary: Maximum Tolerated Dose(MTD)of Temozolomide(TMZ) — 75 mg/m^2
Phase 2 N=18 CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII
Malignant Glioma · Glioblastoma · Brain Cancer
Primary: Number of Treatment Related Adverse Events — 0; 0; 0; 0 adverse events
Phase 1 N=16 Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas
Adult Anaplastic Astrocytoma · Adult Anaplastic Oligodendroglioma · Adult Giant Cell Glioblastoma
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) and Maximum Tolerated Dose (MTD) — 0; 0; 0; 1 Participants
Phase 2 N=10 Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma
MGMT-unmethylated Glioblastoma (GBM) · GBM
Primary: 1-year Overall Survival (OS) — 80 percentage of participants
Phase 2 N=110 Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma
Adult Anaplastic Astrocytoma · Adult Anaplastic Oligodendroglioma · Adult Giant Cell Glioblastoma
Primary: Number of Dose Limiting Toxicity (DLT) Each Dose Level Phase I — 1; 0; 0; 0 dose limiting toxicities
Phase 2 N=158 A Study in Recurrent Glioblastoma (GB)
Glioblastoma
Primary: Overall Survival (OS) — 8.0; 6.7; 7.5 Months
Phase 2 N=33 Nivolumab for Recurrent or Progressive IDH Mutant Gliomas
Gliomas
Primary: Overall Response Rate — 9 percent